Literature DB >> 7783963

A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein epsilon 4 allele.

H Soininen1, O Kosunen, S Helisalmi, A Mannermaa, L Paljärvi, S Talasniemi, M Ryynänen, P Riekkinen.   

Abstract

We measured the activities of choline acetyltransferase (ChAT) in the post mortem frontal cortex in 32 Alzheimer's disease (AD) patients with different apolipoprotein E (apoE) genotypes. The ChAT values were significantly lower for the AD patients with 2 epsilon 4 alleles than for those with 0 epsilon 4 (ANOVA, P < 0.05). The ChAT activities of AD patients carrying 2 or 1 epsilon 4 alleles and those without the epsilon 4 allele also differed significantly: 16.3 +/- 15.2 versus 30.5 +/- 20.6 pmol/mg protein per min, ANOVA, P < 0.05. However, the AD patients carrying the epsilon 4 allele were significantly younger than those with 0 epsilon 4 allele. The study indicates that AD patients carrying the epsilon 4 allele have a more severe cholinergic deficit than the AD patients without the epsilon 4 allele.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7783963     DOI: 10.1016/0304-3940(95)11343-6

Source DB:  PubMed          Journal:  Neurosci Lett        ISSN: 0304-3940            Impact factor:   3.046


  27 in total

Review 1.  Genetic influences on outcome following traumatic brain injury.

Authors:  Barry D Jordan
Journal:  Neurochem Res       Date:  2007-03-07       Impact factor: 3.996

Review 2.  The cognitive psychopharmacology of Alzheimer's disease: focus on cholinergic systems.

Authors:  A D Lawrence; B J Sahakian
Journal:  Neurochem Res       Date:  1998-05       Impact factor: 3.996

3.  Scopolamine-induced impairment as a potential predictor of Alzheimer's disease in individuals with Apolipoprotein E type 4 alleles.

Authors:  N Pomara; K Nolan; G Halpern
Journal:  Neurochem Res       Date:  1995-12       Impact factor: 3.996

Review 4.  Apolipoprotein E4, cholinergic integrity and the pharmacogenetics of Alzheimer's disease.

Authors:  J Poirier
Journal:  J Psychiatry Neurosci       Date:  1999-03       Impact factor: 6.186

5.  The apolipoprotein E allele epsilon 4 does not correlate with the number of senile plaques or neurofibrillary tangles in patients with Alzheimer's disease.

Authors:  M Landén; A Thorsell; A Wallin; K Blennow
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-10       Impact factor: 10.154

6.  Major decrease in the volume of the entorhinal cortex in patients with Alzheimer's disease carrying the apolipoprotein E epsilon4 allele.

Authors:  K Juottonen; M Lehtovirta; S Helisalmi; P J Riekkinen; H Soininen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-09       Impact factor: 10.154

7.  Synaptic pathology in Alzheimer's disease: relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele.

Authors:  K Blennow; N Bogdanovic; I Alafuzoff; R Ekman; P Davidsson
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

8.  Attentional performance, impulsivity, and related neurotransmitter systems in apoE2, apoE3, and apoE4 female transgenic mice.

Authors:  Ingrid Reverte; Fiona Peris-Sampedro; Pia Basaure; Leticia Campa; Cristina Suñol; Margarita Moreno; José Luis Domingo; Maria Teresa Colomina
Journal:  Psychopharmacology (Berl)       Date:  2016-01       Impact factor: 4.530

9.  SPECT and MRI analysis in Alzheimer's disease: relation to apolipoprotein E epsilon 4 allele.

Authors:  M Lehtovirta; H Soininen; M P Laakso; K Partanen; S Helisalmi; A Mannermaa; M Ryynänen; J Kuikka; P Hartikainen; P J Riekkinen
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

10.  Kinetics of angiogenic changes in a new mouse model for hepatocellular carcinoma.

Authors:  Femke Heindryckx; Koen Mertens; Nicolas Charette; Bert Vandeghinste; Christophe Casteleyn; Christophe Van Steenkiste; Dominique Slaets; Louis Libbrecht; Steven Staelens; Peter Starkel; Anja Geerts; Isabelle Colle; Hans Van Vlierberghe
Journal:  Mol Cancer       Date:  2010-08-20       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.